Odyssey Therapeutics, a Phase 2 biotech developing precision therapies for autoimmune diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Odyssey is a biotech focused on developing targeted therapies for autoimmune and inflammatory diseases. The company leverages expertise in immunobiology and drug discovery to identify and inhibit key signaling pathways that drive disease. Its lead programs include oral small-molecule candidates targeting RIPK2 and SLC15A4, with its most advanced drug showing early clinical efficacy in ulcerative colitis and others in preclinical development. Odyssey aims to address conditions such as inflammatory bowel disease and lupus, where treatment options remain limited.
The company previously filed for a $100 million IPO in January 2025 before withdrawing it in June 2025.
The Boston, MA-based company was founded in 2021 and booked $3 million in revenue for the 12 months ended December 31, 2025. It plans to list on the Nasdaq under the symbol ODTX. Odyssey Therapeutics filed confidentially on February 6, 2026. J.P. Morgan, TD Cowen, Cantor Fitzgerald, Wedbush PacGrow, and Oppenheimer & Co. are the joint bookrunners on the deal.
